SELLAS Life Sciences Group has announced significant progress in its REGAL Phase 3 trial of galinpepimut-S (GPS) for treating acute myeloid leukemia, achieving 78 out of 80 necessary overall survival events, with results expected soon. This news, combined with recent amendments to executive employment contracts that suggest potential corporate changes, has enhanced investor interest and speculation regarding merger or acquisition possibilities. While the developing data could significantly impact SELLAS’ valuation, the company currently faces challenges, including no revenue and ongoing losses, making the future landscape uncertain for investors. Despite varying fair value estimates ranging widely, the upcoming GPS readout will be a pivotal moment for the company’s future.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://sg.finance.yahoo.com/news/near-complete-regal-phase-3-210808813.html
